Search the Newsreel

Richardson Electronics, Generac, Columbus McKinnon, Astronics, and Mercury Systems Shares Plummet, What You Need To Know

Richardson Electronics, Generac, Columbus McKinnon, Astronics, and Mercury Systems Shares Plummet, What You Need To Know What Happened? A number of stocks fell in the morning session after the latest industrial production report showed slower-than-expected growth for July. Data from the Federal Reserve indicated …

TScan Therapeutics - Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics - SEC Filing

Amgen has decided to terminate its research collaboration and license agreement with TScan Therapeutics. This information was disclosed via an SEC filing. The full details of this termination can be found in the mentioned SEC filing.

Agenus extends $24.75 million loan maturity, adjusts payment terms with Ocean 1181

Agenus Inc. has extended the maturity date of a $24.75 million loan with Ocean 1181 LLC to November 30, 2029, maintaining a 13.0% annual interest rate. Payment terms include monthly interest in both cash and common stock, along with an extension fee paid in …

The Bull Case For Repligen (RGEN) Could Change Following Raised Guidance On Q2 Outperformance - Learn Why

Generac Holdings Inc. stock underperforms Tuesday when compared to competitors

Generac Holdings Inc. (GNRC) stock fell 4.38% on Tuesday, closing at $211.56, amidst a generally negative trading session for the broader market. This decline broke a two-day winning streak for the company's shares. The S&P 500 Index and Dow Jones Industrial Average also experienced …

Evogene: Q2 Earnings Snapshot

Evogene Ltd. (EVGN) reported a Q2 loss of $1.8 million, or 14 cents per share, with an adjusted loss of 13 cents per share. The agricultural company generated $347,000 in revenue for the period. This financial snapshot was generated using data from Zacks Investment …

Evogene Q2 2026: Loss Narrows 50.0% to -$0.14/Share, Revenue Down 35%

Evogene Ltd. (NASDAQ: EVGN) reported a Q2 2026 loss of $0.14 per share, significantly narrower than anticipated, despite a 35% decline in revenue. While the company showed dramatic year-over-year improvement in loss reduction and maintained its computational platform scale, the revenue decline led to …

Evogene Q2 2026 Deep Dive: EPS Beats, Revenue Down 35%

Evogene Ltd. (EVGN) reported a narrower-than-expected Q2 2026 loss per share, beating consensus by 50% due to aggressive cost-cutting. However, revenue declined by 35%, highlighting that the earnings beat was driven by expense management rather than top-line growth. The company continues to rely on …

CANACCORD GENUITY GROUP INC. THROUGH ITS WEALTH MANAGEMENT BUSINESS IN THE UK & CROWN DEPENDENCIES ANNOUNCES ACQUISITION OF EFG HARRIS ALLDAY

TORONTO and LONDON, Aug. 18, 2026 /CNW/ -- Canaccord Genuity Group Inc. (TSX: CF) (the "Company") is pleased to announce that through its wealth management business in the UK & Crown Dependencies, it has entered into an agreement to acquire the front office teams …

Amgen Inc. stock underperforms Tuesday when compared to competitors despite daily gains

Amgen Inc. stock gained 1.41% on Tuesday, closing at $425.28, despite a generally negative trading session where the S&P 500 and Dow Jones Industrial Average both fell. Despite its daily gains, Amgen underperformed compared to its competitors. This marks the second consecutive day of …

TScan (NASDAQ: TCRX) loses Amgen Crohn’s collaboration

Amgen has terminated its Research Collaboration and License Agreement with TScan Therapeutics (TCRX), impacting over $500 million in potential milestone payments and future royalties related to Crohn's disease research. TScan had previously received a $30 million upfront payment, and will not incur any early …

Biogen Inc. stock underperforms Tuesday when compared to competitors despite daily gains

Shares of Biogen Inc. (BIIB) rose 1.63% on Tuesday to $212.55, breaking a two-day losing streak, despite a generally grim trading session for the broader stock market. The S&P 500 Index fell 0.69% and the Dow Jones Industrial Average declined 0.22%. Despite its daily …

Agenus (NASDAQ: AGEN) to pay part of 13% loan interest in stock

Agenus Inc. (NASDAQ: AGEN) has amended a key debt facility through its subsidiary, extending the maturity date of a $24.75 million loan to November 30, 2029. The interest rate remains at a high 13.0% per annum, with monthly payments and an extension fee partially …

Agenus Extends $24.75M Term Loan to 2029 at 13% With Ocean 1181; Partly Payable in Stock

Agenus has extended its $24.75 million term loan with Ocean 1181 to November 30, 2029, at a 13.0% interest rate. The monthly interest and a $247,500 extension fee will be paid partly in cash and partly in Agenus common stock. This modification aims to …

Legend Biotech (LEGN) RSU grant lifts interim CEO stake to 35,142 shares

Legend Biotech (LEGN) Interim CEO Alan Bash received a grant of 4,908 restricted share units (RSUs) on August 14, 2026, increasing his direct holdings to 35,142 ordinary shares. These RSUs will vest in three equal annual installments starting July 27, 2027, provided he remains …

MacroGenics (MGNX) exec adds 40K shares via option exercise

MacroGenics (MGNX) Senior VP, Research & CSO Ezio Bonvini, reported exercising 40,000 employee stock options at $2.60 per share on August 17, 2026, and holding the acquired common stock. Following this transaction, Bonvini directly holds 185,799 shares of common stock and 88,000 employee stock …

Genpact (NYSE: G) SVP Sameer Dewan sells 14,972 shares

Genpact (NYSE: G) Senior Vice President Sameer Dewan sold a total of 14,972 common shares on August 14, 2026, through open market or private transactions. The shares were sold in two blocks, one at $34.10 per share and another at a weighted average price …

GFUZ: Raised $150 million post-listing to advance fusion milestones and target commercial deployment by 2035

General Fusion Group Ltd. (GFUZ) has secured $150 million post-listing to fund its fusion milestones through 2028. The company is making progress in plasma heating and expanding commercial partnerships, aiming for commercial fusion deployment by 2035. This funding will support the advancement of their …

3 Reasons Why Growth Investors Shouldn't Overlook Mercury General (MCY)

Legend Biotech (NASDAQ: LEGN) targets 19.1M new stock awards

Legend Biotech Corporation (LEGN) will hold its Annual General Meeting on September 24, 2026, to vote on several key proposals, including a significant increase in its equity reserve. The company is seeking shareholder approval to boost its 2020 Restricted Shares Plan by 19.1 million …

Generate (GENB) Report Card: EPS Misses Its Estimate in the Available Record; Price Action: Shares Finish 3.44% Higher in the Current Update - EPS Guidance Update

GrowGeneration (GRWG) Results Breakdown: The EPS Result Is Above Expectation at the Close; Immediate Response: Shares Finish 2.65% Down in the Latest Session - Fiscal Year Earnings

General Fusion heats plasma to 8.4 million degrees toward fusion power

General Fusion (NASDAQ: GFUZ) has released its first public business update since listing on Nasdaq in July 2026, announcing approximately US$150 million in cash to fund its Lawson Machine 26 (LM26) program through 2028. The company reported achieving plasma heating of 0.72 keV (8.4 …

Is Lithium Argentina (TSX:LAR) Entering New Profit Territory?

S&P downgrades Emergent BioSolutions outlook on competition

S&P Global Ratings has downgraded Emergent BioSolutions Inc.'s outlook to negative from stable due to increased competition in the naloxone market, which led to reduced revenue guidance. The ratings agency projects a significant decline in both its commercial and Medical Countermeasures segments' revenue for …

BBVA: Capital Returns And Turkey Exposure Will Shape Fairly Balanced Future Risk Reward

BBVA's fair value estimate has increased to €22.99, influenced by both rising price targets from some banks and caution from others regarding valuation and Turkey-related risks. While some analysts praise BBVA's strong fundamentals and high RoTE, others have downgraded ratings due to the recent …

Casey's (CASY) Quarterly Update: EPS Clears the Reported Estimate in the Latest Reading; Immediate Response: The Stock Records a 1.41% Decrease - Short-Term Outlook

Cogent (COGT) Q1 2026 Earnings: EPS Misses Its Estimate in the Latest Session; Investor Response: The Share Price Sheds 1.35% in Latest Trading - CEO Earnings Statement

CARsgen Therapeutics Holdings (SEHK:2171) Gains On CT0596 IND Clearance, But Is The Valuation Too Rich

Genuine (GPC) Financial Update: Profit Per Share Surpasses Its Benchmark in the Latest Session; Market Reaction: Shares Rise 0.44% - EPS Estimate Trend

Die optimistischen Aussichten für Amgen (AMGN) könnten sich nach der Anhebung der Gewinnprognose für 2026 und dem über den Erwartungen liegenden Ergebnis im zweiten Quartal ändern – erfahren Sie, warum

Las perspectivas alcistas para Amgen (AMGN) podrían cambiar tras la revisión al alza de las previsiones de beneficios para 2026 y los resultados del segundo trimestre, que han superado las expectativas: descubre por qué

Genelux (GNLX) Latest Earnings Reading: EPS Misses Its Estimate in the Latest Reading; Market Reaction: The Market Price Declines 1.67% at the Close - Revenue Inflection Point

The Bull Case For Amgen (AMGN) Could Change Following Raised 2026 Earnings Guidance And Q2 Beat - Learn Why

Amgen Inc. recently reported strong second-quarter 2026 results, with revenues of US$10,054 million and net income of US$2,375 million, leading to raised full-year 2026 guidance. The company now expects total revenue between US$38.20 billion and US$39.40 billion, and GAAP EPS of US$15.80 to US$17.08. …

Lithium (LAR) Quarterly Performance Check: The Bottom-Line Figure Trails Its Comparison; Price Action: Shares Close 5.32% Lower in Latest Trading - Product Revenue Analysis

Ocugen Inc. stock falls Tuesday, underperforms market

Ocugen Inc. (OCGN) shares fell 2.55% on Tuesday, closing at $1.34, significantly underperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines. The company's stock is currently 50.83% below its 52-week high of $2.73, achieved in March.